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Abstract
Purpose This study explored the superiority of temozolomide (TMZ) + interferonβ (IFNβ) to standard TMZ as treatment 
for newly diagnosed glioblastoma (GBM) via randomized phase II screening design.
Experimental design Eligibility criteria included histologically proven GBM, with 50% of the tumor located in supratentorial 
areas, without involvement of the optic, olfactory nerves, and pituitary gland and without multiple lesions and dissemina-
tion. Patients in the TMZ + radiotherapy (RT) arm received RT (2.0 Gy/fr/day, 30 fr) with TMZ (75 mg/m2, daily) followed 
by TMZ maintenance (100–200 mg/m2/day, days 1–5, every 4 weeks) for 2 years. Patients in the TMZ + IFNβ + RT arm 
intravenously received IFNβ (3 MU/body, alternative days during RT and day 1, every 4 weeks during maintenance period) 
and TMZ + RT. The primary endpoint was overall survival (OS). The planned sample size was 120 (one-sided alpha 0.2; 
power 0.8).
Results Between Apr 2010 and Jan 2012, 122 patients were randomized. The median OS with TMZ + RT and 
TMZ + IFNβ + RT was 20.3 and 24.0 months (HR 1.00, 95% CI 0.65–1.55; one-sided log rank P = 0.51). The median pro-
gression-free survival times were 10.1 and 8.5 months (HR 1.25, 95% CI 0.85–1.84). The incidence of neutropenia with the 
TMZ + RT and the TMZ + IFNβ + RT (grade 3–4, CTCAE version 3.0) was 12.7 versus 20.7% during concomitant period and 
was 3.6 versus 9.3% during maintenance period. The incidence of lymphopenia was 54.0 versus 63.8% and 34.5 versus 41.9%.
Conclusions TMZ + IFNβ + RT is not considered as a candidate for the following phase III trial, and TMZ + RT remained to 
be a most promising treatment. This trial was registered with the UMIN Clinical Trials Registry: UMIN000003466.
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HR  Hazard ratio
JNS  Japan Neurosurgical Society
IARC  International Agency for Research on Cancer
Introduction
Gliomas account for approximately 40% of all brain tumors 
and are thus the most common primary tumors of the cen-
tral nervous system (CNS) [1]. In particular, glioblastoma 
(GBM) is one of the most frequent brain tumors in the CNS 
in adults and is highly malignant, with a median survival 
time of about 1 year from diagnosis [2]. An international 
randomized trial by the European Organisation for Research 
and Treatment of Cancer (EORTC)/National Cancer Insti-
tute of Canada that compared concomitant radiotherapy 
(RT) and temozolomide (TMZ) to RT alone clearly dem-
onstrated the benefits of adjuvant TMZ chemotherapy for 
GBM patients [3]. The median OS in the GBM patients who 
received RT + TMZ in trials in Europe [3], the United States 
[4], and an international collaboration (AVAglio) [5] were 
14.6, 16.8, and 15.7 months, respectively.
Since then, TMZ has been the current first-line chemo-
therapeutic agent for GBM. A subgroup analysis in the trial 
above revealed the effectiveness of epigenetic silencing of 
the O6-methylguanine-DNA methyltransferase (MGMT) 
gene via promoter methylation, with longer survival, in 
patients with primary GBM. It also suggested the benefits 
of agents targeting MGMT combining with TMZ plus radio-
therapy [6]. Interferonβ (IFNβ) exerts pleiotropic biological 
effects [7, 8] and has been widely used either as a single 
agent or in combination with other antitumor agents in the 
treatment of malignant gliomas and melanomas [9]. In the 
treatment of malignant gliomas, IFNβ can act as a drug 
sensitizer, and it enhances the toxicity of chemotherapeu-
tic agents against various neoplasms when administered in 
combination with nitrosourea [10]. Combination therapy 
with IFNβ and nitrosourea has been used primarily in the 
treatment of gliomas in Japan [11]. In our previous in vitro 
study of human glioma cells, we found that IFNβ mark-
edly enhanced chemosensitivity to TMZ [12]. This find-
ing suggested that one of the major mechanisms by which 
IFNβ enhances chemosensitivity is the downregulation of 
MGMT transcription via p53 induction. This effect was also 
observed in an experimental animal model [13]. The results 
of these 2 studies suggested that chemotherapy with IFNβ 
and TMZ with concomitant RT might further improve the 
clinical outcome of patients with malignant gliomas, com-
paring to chemotherapy with TMZ alone and concomitant 
RT. Based on these results, we translated the preclinical evi-
dence to clinical studies. A phase I study showed the safety 
and feasibility of chemotherapy with IFNβ and TMZ com-
bined with concomitant radiotherapy [14, 15]. In addition, 
a retrospective study demonstrated that addition of IFNβ for 
newly diagnosed primary GBM achieved a favorable out-
come, particularly in patients with an unmethylated MGMT 
promoter [16].
Based on the rationale shown above, we conducted a ran-
domized screening phase II trial of chemoradiotherapy with 
TMZ plus IFNβ in comparison with chemoradiotherapy with 
TMZ alone for newly diagnosed GBM (JCOG0911 INTE-
GRA study), as the Japan Clinical Oncology Group (JCOG) 
study to explore the superiority of TMZ + IFNβ therapy to 




For inclusion in the study, patients had to meet all of the 
following criteria: histologically proven newly diagnosed 
GBM based upon WHO 2007 (IARC 4th edition); 50% of 
the tumor located in supratentorial areas, without involve-
ment of the optic, olfactory nerves, and pituitary gland and 
without multiple, disseminated, or large tumors in which the 
planned irradiated target volume exceeds one-third of the 
whole brain volume; enrollment 3–20 days after surgery; 
age between 20 and 75 years; Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0–2 or 3 (only if 
caused by the tumor); no history of previous chemotherapy 
or radiotherapy; appropriate organ function and written 
informed consent.
Treatment
Patients in the TMZ + RT arm received RT (2.0 Gy/fr/day, 
30 fr) with TMZ (75 mg/m2, daily) followed by maintenance 
of TMZ (100–200 mg/m2/day, days 1–5, every 4 weeks) for 
2 years because (1) optimal duration of maintenance temo-
zolomide had not been determined, and (2) the majority of 
the investigators in this study agreed that the maintenance 
temozolomide period was > 12 months.
Patients in the TMZ + IFNβ + RT arm intravenously 
received IFNβ (3 MU/body on day 1, day 3, and day 5 during 
RT concomitant period and day 1, every 4 weeks during the 
maintenance period) in addition to TMZ + RT (Fig. 1). We 
determined IFN-beta dosage based on previously published 
trials, including a Phase I trial [11, 14, 17–20].
RT with concomitant chemotherapy was started within 
3 weeks after the surgery. Three-dimensional conformal 
radiotherapy was planed. Quality assurance reviews were 
performed at the Radiotherapy Support Center under super-
vision of JCOG Radiotherapy Committee, with feedback 
sent to each institution by the RT study coordinator (Minako 
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Sumi). The minimum and maximum doses in the planning 
target volume (PTV) should comprise between 90 and 110% 
of the reference point dose of the International Commis-
sion on Radiation Units. Gross tumor volume (GTV) was 
defined as residual tumor, with or without enhancement on 
computed tomography or magnetic resonance imaging. The 
clinical target volume 1 (CTV1) included GTV, the resec-
tion cavity, and surrounding edema (high-intensity area on 
T2-weighted or fluid-attenuated inversion recovery image) 
plus a 1.5-cm margin. The CTV2 included GTV and the 
resection cavity plus a 1.5-cm margin. PTV was defined 
as CTV plus a margin of 0.5 cm. The doses for PTV1 and 
PTV2 were 50 Gy in 25 fractions and 10 Gy in 5 fractions, 
respectively.
Study design
This trial was designed as a multicenter, prospective, rand-
omized screening phase II study to explore the superiority 
of TMZ + IFNβ therapy to TMZ alone in terms of OS in 
patients with newly diagnosed GBM and to decide whether 
TMZ + IFNβ should be evaluated in a succeeding confirma-
tory phase III trial. Patients were randomized using a mini-
mization method with biased-coin assignment to receive 
either the standard arm (TMZ + RT) or the experimental 
arm (TMZ + IFNβ + RT) at the JCOG Data Center, adjusting 
for factors including institution, age (≤ 49 vs. ≥ 50 years), 
ECOG performance status (0 vs. 1 or 2 [3 if this was due 
to brain tumor]), and residual tumor after resection (pre-
sent vs. absent). The study protocol was approved by the 
JCOG Protocol Review Committee and the institutional 
review board of each participating institution, and carried 
out in accordance with the Declaration of Helsinki. This 
trial was registered at the UMIN Clinical Trials Registry as 
UMIN000003466 (http://www.umin.ac.jp/ctr/index .htm).
Statistical consideration
The primary endpoint was OS. OS was calculated from 
the date of randomization until death from any cause. The 
secondary endpoints were progression-free survival (PFS), 
complete response rate, overall response rate, and adverse 
events. PFS was calculated from the date of randomiza-
tion until the date of documented progression or death. 
Responses were evaluated according to Response Evalua-
tion Criteria in Solid Tumors version 1.0. Toxicities were 
evaluated according to the Common Terminology Criteria 
for Adverse Events (CTCAE) version 3.0.
The planned sample size was 120 and the expected num-
ber of events was 70, with a one-sided alpha of 0.2 and 
power of 0.8 to detect a difference between arms. The 1-year 
survival was presumed to be 65% in the TMZ + RT arm, and 
Newly diagnosed 
glioblastoma 





TMZ: 100-200mg/m² days 1 to 5 
every 4wks for 2 yrs
Arm B
Concomitant TMZ+IFNβ+RT




IFN: 3 MU/body,  day 1
every 4wks for 2yrs
Resecon or biopsy
TMZ: 75mg/m² daily during RT (30 fr x 2Gy)
*Adjusng factors     
• Instute 
•Age㸦≤ 49 vs. ≥ 50) 
•ECOG PS




Fig. 1  Patient flow diagram of a randomized screening phase II trial of chemoradiotherapy with interferonβ plus temozolomide in comparison 
with chemoradiotherapy with temozolomide alone for newly diagnosed glioblastoma
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was expected to be 75% in the TMZ + IFNβ + RT arm. The 
planned accrual and follow-up period were 1.5 and 2 years, 
respectively. Primary analysis was conducted 2 year after 
the accrual completion.
One interim analysis was scheduled after the half of the 
planned sample size was enrolled to assess the futility of this 
study. Multiplicity was not taken into consideration because 
terminating the trial due to superiority of TMZ + IFNβ + RT 
arm was not planned. Results of interim analysis were 
reviewed by the JCOG Data and Safety Monitoring Com-
mittee and investigators were masked to the results.
OS was analyzed by the stratified log-rank test with 
residual tumor after resection (present vs. absent) as a strata. 
Hazard ratio was estimated by stratified Cox proportional 
hazard model with residual tumor after resection (present vs. 
absent) as a strata. PFS was analyzed by the unstratified log-
rank test and unstratified Cox proportional hazard model. 
OS and PFS curves were estimated by the Kaplan–Meier 
method. The efficacy analyses were by intention-to treat and 
safety analyses were by all patients who received protocol 
treatment. All analyses were performed by the JCOG Data 
Center using SAS 9.2 (SAS Institute, Cary, NC).
Results
CONSORT diagram and characteristics of the ITT 
population
From April 2010 to January 2012, 122 patients were 
accrued, of whom 63 and 59 patients were assigned to 
the TMZ + RT and TMZ + IFNβ + RT arms, respectively 
(Fig. 2). All the tumors were proven to be GBM by the 
central pathological review. In addition, IDH1/2 mutation 
in each tumor was not detected though anti-IDH1-R132H 
immunohistochemistry and Sanger sequencing (Table 1). 
The patients’ characteristics were as follows: median age 
(61 years [range 22–75 years] vs. 61 years [range 30–73 
years]), male/female (38/25 vs. 35/24), ECOG perfor-
mance status 0/1–3 (16/47 vs. 12/47), residual tumor 
resection absent/present (31/32 vs. 33/26) (Table 1). One 
patient in the TMZ + IFNβ + RT arm was off-protocol 
before the initiation of protocol treatment owing to liver 
44 started maintenance TMZ+IFNβ
1  connued protocol treatment
7 completed maintenance treatment
36 disconnued maintenance treatment
122 randomized
63 assigned to TMZ
63 eligible (63 eligible by central review)
59 assigned to TMZ +IFNβ 
59 eligible (59 eligible by central review)
63 completed Concomitant TMZ+RT 
55 started maintenance TMZ 
10 completed maintenance treatment
45 disconnued maintenance treatment
8 terminated
56 completed Concomitant TMZ+IFNβ+RT
2 terminated  
58 started Concomitant  TMZ+IFNβ+ RT
1 off-protocol
63 started Concomitant TMZ+RT 
12 terminated
Fig. 2  Consort diagram. From April 2010 to January 2012, 122 patients were accrued, of whom 63 and 59 patients were assigned to the 
TMZ + RT and TMZ + IFNβ + RT arms, respectively
Table 1  Characteristics of the ITT population
TMZ + RT (n = 63) TMZ + IFNβ + RT 
(n = 59)











 No mutation 57 58
 Not examined 6 1
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dysfunction and thus was excluded from the safety analy-
sis. Two patients in the TMZ + IFNβ + RT arm terminated 
protocol treatment during the concomitant period due 
to progression and adverse events (grade 3 anorexia and 
grade 2 erythema multiforme) and 12 patients terminated 
protocol treatment due to progression, adverse events and 
patient refusal with adverse events (7, 3, and 2 patients) in 
the interval between the concomitant and the maintenance 
treatments. In the TMZ + RT arm, 8 patients terminated 
protocol treatment during the interval between the con-
comitant and the maintenance treatments because of pro-
gression or adverse events (7 and 1 patients). In the main-
tenance period, 55 patients started TMZ, but 45 patients 
terminated the maintenance treatment owing to progres-
sion, adverse events, and patient refusal with adverse 
events (34, 3, and 6 patients) in the TMZ + RT arm. In 
the TMZ + IFNβ + RT, 44 patients started TMZ + IFNβ, 
but 36 patients terminated the maintenance treatment 
owing to progression, adverse events, patient refusal 
with adverse events, and another reason (30, 1, 3, and 1 
patients) (Table 2). One treatment related death (TRD) was 
observed in TMZ + IFNβ + RT arm during the maintenance 
therapy (severe renal failure). The post-protocol treatments 
are listed in Table 3. Chemotherapy using either TMZ or 
TMZ + IFNβ was administered as post-protocol treatments 
in 11 and 14 patients, respectively. Other chemotherapies 
were applied in 1 and 6 patients. Bevacizumab was used 
in 3 patients in the TMZ + RT arm.
Overall and progression‑free survival
The median survival time was 20.3 months (95% CI 
15.4–26.9 months) and 24.0 months (95% CI 18.8–27.4 
months) in the TMZ + RT arm and the TMZ + IFNβ + RT 
arm, respectively (HR 1.00, 95% CI 0.65–1.55; one-sided 
log rank P = 0.51). OS did not statistically differ between 
the two arms (Fig. 3a).
The median PFS was 10.1 months (95% CI 7.5–11.8 
months) and 8.5 months (95% CI 6.6–11.9 months) in the 
TMZ + RT arm and the TMZ + IFNβ + RT arm, respectively 
(HR 1.25, 95% CI 0.85–1.84; two-sided P = 0.25) (Fig. 3b).
Subgroup analyses were performed for OS by sex (male/
female), age (≤ 49 years/≥ 50 years), residual tumor after 
resection (absent/present) and ECOG PS (0/1/2–3) (Fig. 4). 
Male, Younger patients (≤ 49 years) and ECOG PS 0 in the 
TMZ + IFNβ + RT arm showed good OS compared with RT/
TMZ arm.
Adverse events
The incidence of grade 3 and 4 neutropenia was higher in 
the TMZ + IFNβ + RT arm (Table 4). The difference was 
more marked in the patients aged ≥ 50 years. Among the 
non-hematological adverse events, fever, nausea/vomit-
ing, and appetite loss tended to be more frequent in the 
TMZ + IFNβ + RT arm.
Discussion
IFNs exert pleiotropic antitumor effects by direct anticancer 
mechanisms though p53 induction and miR-21 downregula-
tion or by regulating the immune system through the CD8 
lymphocyte and macrophage activation [7]. This study was 
a randomized screening phase II trial to explore the superi-
ority of TMZ + IFNβ therapy to TMZ alone for the patients 
with newly diagnosed GBM. In the present study, the supe-
riority of TMZ + IFNβ + RT to TMZ + RT in OS was not 
demonstrated.
There are some possibilities that we failed to show 
the superiority of TMZ + IFNβ + RT to TMZ + RT. One 
potential reason is that TMZ + IFNβ + RT treatment was 
more toxic than expected. Before we started this trial, we 
assumed that additional IFNβ would not increase much 
toxicity because it had been suggested in some reports 
using nitrosourea anti-tumor agent with IFNβ. How-
ever, the proportion of severe (grade 3–4) hematological 
and non-hematological adverse events was higher in the 
TMZ + IFNβ + RT arm than in the TMZ + RT arm, which 




TMZ + RT (n = 63) TMZ + IFNβ + RT 
(n = 56)
n = 119
0 8(12.7%) 12(21.4%) 20
1–12 39(61.9%) 29(51.8%) 68
13–31 16(25.4%) 15(26.8%) 31






1. Same as protocol treatment 11 14
 TMZ 9 5
 TMZ + IFNβ 2 9
2. Other chemotherapy (ACNU, Irinote-
can, ICE, other TMZ regimens)
1 6
3.SRS, SRT 4 7
4. Surgery 18 11
5. Others 5 1
 Bevacizumab 3 0
 Vaccine 2 1































































Strafied HR (95%CI) 1.00 (0.65-1.55)
One-sided p-value 








Unstrafied HR (95%CI) 1.25 (0.85-1.84)
Two-sided p-value 
by unstrafied log-rank test P=0.25
a b 
Fig. 3  Clinical outcomes. The median survival time was 20.3 
months (95% CI 15.4–26.9 months) and 24.0 months (95% CI 
18.8–27.4 months) in the TMZ + RT arm and the TMZ + IFNβ + RT 
arm, respectively (HR 1.00, 95% CI 0.65–1.55; one-sided log rank 
P = 0.51). OS did not statistically differ between the two arms (a). 
The median PFS was 10.1 months (95% CI 7.5–11.8 months) and 
8.5 months (95% CI 6.6–11.9 months) in the TMZ + RT arm and the 
TMZ + IFNβ + RT arm, respectively (HR 1.25, 95% CI 0.85–1.84; 
two-sided P = 0.25) (b)
Favors TMZ+RTFavors TMZ+INFβ+RT
Subgroup analysis of OS

















0.78 [0.46 - 1.32]
1.29 [0.61 - 2.71]
0.45 [0.16 - 1.29]
1.15 [0.71 - 1.85]
0.94 [0.49 - 1.79]
1.12 [0.62 - 2.01]
0.74 [0.33 - 1.66]
0.89 [0.42 - 1.90]
1.15 [0.58 - 2.31]












Fig. 4  Subgroup analyses were performed for OS by sex (male/
female), age (≤ 49  years/≥ 50  years), residual tumor after resection 
(absent/present) and ECOG PS (0/1/2–3). Male, Younger patients 
(≤ 49 years) and ECOG PS 0 in the TMZ + IFNβ + RT arm showed 
good OS compared with RT/TMZ arm
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implied such unexpected severe toxicities could cause 
negative impact on the survival in the TMZ + IFNβ + RT 
arm. Due to the severe toxicities, treatment compliance 
was also deteriorated in the TMZ + IFNβ + RT arm. In fact, 
the number of patients who terminated protocol treatment 
before the start of the maintenance treatments was larger 
in the TMZ + IFNβ + RT arm, which was possibly caused 
by the toxicities as mentioned above. MGMT methylation 
status has not been investigated yet, but we are planning to 
evaluate the biomarkers including MGMT gene expression 
and methylation using tumor tissues and blood samples.
Subgroup analyses showed IFNβ could be possibly 
beneficial for younger, male, better PS, no residual tumor 
patients. It may suggest that the better tolerability against 
IFNβ toxicities might be predictive factors of IFNβ effi-
cacy, but further studies would be needed to confirm this 
hypothesis.
As the future direction, we will seek for the promising 
combination therapy with TMZ + RT and other agents than 
IFNβ as a candidate of the following study for GBM. Now 
we just started a randomized phase III trial to confirm the 
superiority of dose-dense TMZ (ddTMZ) followed by beva-
cizumab at ddTMZ failure to bevacizumab alone for patients 
with first recurrence or progression of GBM (JCOG1308C).
In conclusion, although the combination therapy of 
TMZ + IFNβ + RT showed favorable survival, the superi-
ority of TMZ/IFNβ + RT to TMZ + RT in overall survival 
was not demonstrated. Therefore TMZ + IFNβ + RT was not 
considered promising as the test treatment in the following 
phase III study for newly diagnosed GBM and TMZ + RT 
remained to be a most promising treatment.
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Table 4  (a) Adverse events (concomitant chemoradiotherapy), (b) adverse events (maintenance therapy)
According to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
a Data of one patient is missing
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 Skin rash 13 (20.6) 1 (1.6) 0 4 (6.9) 0 0
(b) TMZ + RT (N = 55) TMZ + IFNβ + RT (N = 43)a
Grade 1–2 (%) Grade 3 (%) Grade 4 (%) Grade 1–2 (%) Grade 3 (%) Grade 4 (%)
Hematological
 Neutropenia 31 (56.4) 2 (3.6) 0 21 (48.8) 4 (9.3) 0
 Lymphopenia 29 (52.7) 17 (30.9) 2 (3.6) 22 (51.2) 17 (39.5) 1 (2.3)
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 Febrile neutropenia – 0 0 – 0 0
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 Hyponatremia 11 (20.0) 0 0 7 (16.3) 2 (4.7) 0
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634 Journal of Neuro-Oncology (2018) 138:627–636
1 3
was supported in part of the National Cancer Center Research and 
Development Fund (20S-4, 23-A-20, 26-A-4, 29-A-3), the Health and 
Labour Science Research Grant (H20-19), and the Grant-in Aid for 
Cancer Research (H23-013) from the ministry of Health, Labour and 
Welfare, Japan.
Compliance with ethical standards 
Conflict of interest T.W. has received research funding from Toray Co, 
Ltd, and MSD Co. Ltd. K.S. received honorarium fundings from MSD. 
M.N. received honorarium and research fundings from MSD, Chugai, 
and Eisai, and research funding from Daiichi-Sankyo. R.N. received 
honorarium and research fundings from MSD, Chugai, and Eisai. The 
other authors declare that they have no conflict of interest. All authors 
have registered online Self-reported COI Disclosure Statement Forms 
through the website for Japan Neurosurgical Society members.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky 
Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical 
report: primary brain and other central nervous system tumors 
diagnosed in the United States in 2010–2014. Neuro Oncol 
19:v1–v88. https ://doi.org/10.1093/neuon c/nox15 8
 2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, 
Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau 
P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari 
K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, 
Lacombe D, Cairncross JG, Mirimanoff RO, European Organi-
sation for Research and Treatment of Cancer Brain Tumour and 
Radiation Oncology Groups, National Cancer Institute of Can-
ada Clinical Trials Group (2009) Effects of radiotherapy with 
concomitant and adjuvant temozolomide versus radiotherapy 
alone on survival in glioblastoma in a randomised phase III 
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 
10:459–466 https ://doi.org/10.1016/S1470 -2045(09)70025 -7
 3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, 
Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn 
U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier 
A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, 
European Organisation for Research and Treatment of Cancer 
Brain Tumor and Radiotherapy Groups, National Cancer Insti-
tute of Canada Clinical Trials Group (2005) Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. N 
Engl J Med 352: 987–996 https ://doi.org/10.1056/NEJMo a0433 
30
 4. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal 
DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won 
M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, 
Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman 
EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized 
trial of bevacizumab for newly diagnosed glioblastoma. N Engl 
J Med 370:699–708. https ://doi.org/10.1056/NEJMo a1308 573
 5. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishi-
kawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, 
Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Beva-
cizumab plus radiotherapy-temozolomide for newly diag-
nosed glioblastoma. N Engl J Med 370:709–722. https ://doi.
org/10.1056/NEJMo a1308 345
 6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, 
Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, 
Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer 
RC, Stupp R (2005) MGMT gene silencing and benefit from 
temozolomide in glioblastoma. N Engl J Med 352:997–1003
 7. Galani V, Papadatos SS, Alexiou G, Galani A, Kyritsis AP 
(2017) In vitro and in vivo preclinical effects of type I IFNs 
on gliomas. J Interferon Cytokine Res 37:139–146. https ://doi.
org/10.1089/jir.2016.0094
 8. GuhaSarkar D, Su Q, Gao G, Sena-Esteves M (2016) Systemic 
AAV9-IFNbeta gene delivery treats highly invasive glioblas-
toma. Neuro Oncol 18:1508–1518. https ://doi.org/10.1093/
neuon c/now09 7
 9. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, 
Silverman RH, Borden EC (2003) Apoptosis and interferons: 
role of interferon-stimulated genes as mediators of apoptosis. 
Apoptosis 8:237–249
 10. Kawaji H, Tokuyama T, Yamasaki T, Amano S, Sakai N, Namba 
H (2015) Interferon-beta and temozolomide combination 
therapy for temozolomide monotherapy-refractory malignant 
gliomas. Mol Clin Oncol 3:909–913. https ://doi.org/10.3892/
mco.2015.542
 11. Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, 
Taniguchi K, Ohno T, Nagasaka T, Yoshida J (2000) Initial 
and maintenance combination treatment with interferon-beta, 
MCNU (Ranimustine), and radiotherapy for patients with previ-
ously untreated malignant glioma. J Neurooncol 49:57–62
 12. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Miz-
uno M, Yoshida J (2005) IFN-beta down-regulates the expres-
sion of DNA repair gene MGMT and sensitizes resistant glioma 
cells to temozolomide. Cancer Res 65:7573–7579. https ://doi.
org/10.1158/0008-5472.CAN-05-0036
 13. Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shi-
mato S, Ito M, Yoshida J (2007) A combination of IFN-beta and 
temozolomide in human glioma xenograft models: implication 
of p53-mediated MGMT downregulation. Cancer Chemother 
Pharmacol 61:653–659
 14. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Hashi-
moto N, Takahashi J, Aoki T, Sugiyama K, Ogura M, Natsume 
A, Yoshida J (2011) A multicenter phase I trial of combina-
tion therapy with interferon-beta and temozolomide for high-
grade gliomas (INTEGRA study): the final report. J Neurooncol 
104:573–577. https ://doi.org/10.1007/s1106 0-011-0529-1
 15. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, 
Yoshimine T, Hashimoto N, Aoki T, Kurisu K, Natsume A, 
Ogura M, Yoshida J (2008) A multicenter phase I trial of inter-
feron-beta and temozolomide combination therapy for high-
grade gliomas (INTEGRA study). Jpn J Clin Oncol 38:715–718. 
https ://doi.org/10.1093/jjco/hyn09 5
 16. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, 
Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T (2011) 
Benefits of interferon-beta and temozolomide combination 
therapy for newly diagnosed primary glioblastoma with the 
unmethylated MGMT promoter: a multicenter study. Cancer 
117:1721–1730. https ://doi.org/10.1002/cncr.25637 
 17. Yoshida J, Kajita Y, Wakabayashi T, Sugita K (1994) Long-term 
follow-up results of 175 patients with malignant glioma: impor-
tance of radical tumour resection and postoperative adjuvant 
therapy with interferon, ACNU and radiation. Acta Neurochir 
127:55–59
 18. Hatano N, Wakabayashi T, Kajita Y, Mizuno M, Ohno T, 
Nakayashiki N, Takemura A, Yoshida J (2000) Efficacy of post 
635Journal of Neuro-Oncology (2018) 138:627–636 
1 3
operative adjuvant therapy with human interferon beta, MCNU 
and radiation (IMR) for malignant glioma: comparison among 
three protocols. Acta Neurochir 142:633–638 (discussion 639)
 19. Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T 
(2005) Human interferon beta, nimustine hydrochloride, and 
radiation therapy in the treatment of newly diagnosed malignant 
astrocytomas. J Neurooncol 72:57–62. https ://doi.org/10.1007/
s1106 0-004-2160-x
 20. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, 
Vermeulen S, Nelson DF, Mehta MP, Yung WK, Radiation 
Therapy Oncology G (2006) Phase II Radiation Therapy Oncol-
ogy Group trial of conventional radiation therapy followed by 
treatment with recombinant interferon-beta for supratentorial 
glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol 
Phys 66:818–824. https ://doi.org/10.1016/j.ijrob p.2006.05.021
Affiliations
Toshihiko Wakabayashi1 · Atsushi Natsume1  · Junki Mizusawa2 · Hiroshi Katayama2 · Haruhiko Fukuda2 · 
Minako Sumi3 · Ryo Nishikawa4 · Yoshitaka Narita5 · Yoshihiro Muragaki6 · Takashi Maruyama6 · Tamio Ito7 · 
Takaaki Beppu8 · Hideo Nakamura9 · Takamasa Kayama10 · Shinya Sato10 · Motoo Nagane11 · Kazuhiko Mishima4 · 
Yoko Nakasu12 · Kaoru Kurisu13 · Fumiyuki Yamasaki13 · Kazuhiko Sugiyama14 · Takanori Onishi15 · Yasuo Iwadate16 · 
Mizuhiko Terasaki17 · Hiroyuki Kobayashi18 · Akira Matsumura19 · Eiichi Ishikawa19 · Hikaru Sasaki20 · 
Akitake Mukasa21 · Takayuki Matsuo22 · Hirofumi Hirano23 · Toshihiro Kumabe24,25 · Nobusada Shinoura26 · 
Naoya Hashimoto27 · Tomokazu Aoki28 · Akio Asai29 · Tatsuya Abe30 · Atsuo Yoshino31 · Yoshiki Arakawa32 · 
Kenichiro Asano33 · Koji Yoshimoto34 · Soichiro Shibui5 · Members of Japan Clinical Oncology Group Brain Tumor 
Study Group (JCOG-BTSG)
1 Department of Neurosurgery, Nagoya University Graduate 
School of Medicine, Nagoya, Japan
2 JCOG (Japan Clinical Oncology Group) Data 
Center/Operations Office, National Cancer Center Hospital, 
Tokyo, Japan
3 Radiation Oncology Department, Cancer Institute Hospital, 
Tokyo, Japan
4 Department of Neuro-Oncology/Neurosurgery, Saitama 
Medical University International Medical Center, Saitama, 
Japan
5 Department of Neurosurgery and Neuro-Oncology, National 
Cancer Center Hospital, Tokyo, Japan
6 Department of Neurosurgery, Tokyo Women’s Medical 
University, Tokyo, Japan
7 Department of Neurosurgery, Nakamura Memorial Hospital, 
Sapporo, Japan
8 Department of Neurosurgery, Iwate Medical University, 
Morioka, Japan
9 Department of Neurosurgery, Kumamoto University 
Graduate School of Medicine, Kumamoto, Japan
10 Department of Neurosurgery, Yamagata University Graduate 
School of Medicine, Yamagata, Japan
11 Department of Neurosurgery, Kyorin University Faculty 
of Medicine, Mitaka, Japan
12 Department of Neurosurgery, Shizuoka Cancer Center, 
Shizuoka, Japan
13 Department of Neurosurgery, Hiroshima University, 
Graduate School of Biomedical and Health Sciences, 
Hiroshima, Japan
14 Department of Clinical Oncology & Neuro-oncology 
Program, Hiroshima University Hospital, Hiroshima, Japan
15 Department of Neurosurgery, Ehime University Graduate 
School of Medicine, Ehime, Japan
16 Department of Neurosurgery, Chiba University Graduate 
School of Medicine, Chiba, Japan
17 Department of Neurosurgery, Kurume University Graduate 
School of Medicine, Kurume, Japan
18 Department of Neurosurgery, Hokkaido University Graduate 
School of Medicine, Sapporo, Japan
19 Department of Neurosurgery, Faculty of Medicine, 
University of Tsukuba, Tsukuba, Japan
20 Department of Neurosurgery, Keio University School 
of Medicine, Tokyo, Japan
21 Department of Neurosurgery, The University of Tokyo 
Hospital, Tokyo, Japan
22 Department of Neurosurgery, Nagasaki University Graduate 
School of Medicine, Nagasaki, Japan
23 Department of Neurosurgery, Kagoshima University 
Graduate School of Medical and Dental Sciences, 
Kagoshima, Japan
24 Department of Neurosurgery, Tohoku University Graduate 
School of Medicine, Sendai, Japan
25 Present Address: Department of Neurosurgery, Kitasato 
University School of Medicine, Kanagawa, Japan
26 Department of Neurosurgery, Tokyo Metropolitan Cancer 
and Infectious Disease Center Komagome Hospital, Tokyo, 
Japan
27 Department of Neurosurgery, Osaka University Graduate 
School of Medicine, Suita, Japan
28 Department of Neurosurgery, Kitano Hospital, Osaka, Japan
29 Department of Neurosurgery, Kansai Medical University, 
Osaka, Japan
30 Department of Neurosurgery, Oita University Faculty 
of Medicine, Yufu, Japan
31 Department of Neurological Surgery, Nihon University 
Graduate School of Medicine, Tokyo, Japan
636 Journal of Neuro-Oncology (2018) 138:627–636
1 3
32 Department of Neurosurgery, Kyoto University Graduate 
School of Medicine, Kyoto, Japan
33 Department of Neurosurgery, Hirosaki University Graduate 
School of Medicine, Hirosaki, Japan
34 Department of Neurosurgery, Graduate School of Medical 
Sciences, Kyushu University, Fukuoka, Japan
